Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
1-15 of 237
More Than a Myopathy: The Lived Experience of TK2d
NeuroFrontiersMore Than a Myopathy: The Lived Experience of TK2d
Outcome Measures Capture Progression in Late-Onset TK2d
NeuroFrontiersOutcome Measures Capture Progression in Late-Onset TK2d
ADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
NeuroFrontiersADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
ADHD Is Linked to a Broad Burden of GI Symptoms
NeuroFrontiersADHD Is Linked to a Broad Burden of GI Symptoms
Untangling ADHD from Depression, Anxiety, and Substance Use Disorder
NeuroFrontiersUntangling ADHD from Depression, Anxiety, and Substance Use Disorder
Jill RachBeisel, MD
James Swanson, PhD
- advertisement
Diagnosing Adult ADHD in the Social Media Era
NeuroFrontiersDiagnosing Adult ADHD in the Social Media Era
Jill RachBeisel, MD
James Swanson, PhD
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS
Shannon Raber, MS, CPNP, RN
Bridget Archambault, MSN, CPNP
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Project Oncology®Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Shelina Ramnarine, PhD
Mohamed Abdelbaki, MD
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Project Oncology®3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Alexandria May, PharmD, BCPS
Daniel Landi, MD
Rethinking Migraine Prevention: Where CGRP-Targeting Therapies Fit
NeuroFrontiersRethinking Migraine Prevention: Where CGRP-Targeting Therapies Fit
Alexandria May, PharmD, BCPS
Nina Riggins, MD
- advertisement
Treating ADHD in the Presence of Comorbidities
NeuroFrontiersTreating ADHD in the Presence of Comorbidities
Roberto Olivardia, PhD
Long-Term ADHD Treatment: Examining Stimulant Tolerance
NeuroFrontiersLong-Term ADHD Treatment: Examining Stimulant Tolerance
James Swanson, PhD
Supporting Students with ADHD and Learning Differences
NeuroFrontiersSupporting Students with ADHD and Learning Differences
Roberto Olivardia, PhD
